NovaPort twin, the Newest Double-Lumen Cannula, Approved
Novalung adds the unique double-lumen cannula to its expanding portfolio of products for the extrapulmonary treatment of lung failure. Now only a single cannula is required instead of two.
The NovaPort® twin cannula was specifically designed for veno-venous vascular access for the iLA activve® system - the Allrounder for extrapulmonary lung support. The iLA activve® system can now be applied more rapidly, since cannulation with the NovaPort® twin only requires a single vein rather than the two vessels previously needed. Blood is drawn from the patient and - after passing through the iLA Membrane Ventilator® - returned to the body through the same cannula, which consists of two separate lumens.
The NovaPort® twin cannula enables the use of the jugular vein in the patient’s neck, rather than requiring femoral vessels in the groin, and thus supports the therapeutic goal of mobilizing the patient early on while treatment with the iLA activve® continues. Patient positioning and mobilisation procedures with the NovaPort® twin cannula will be familiar to nurses and physicians alike from treating hemofiltration patients. Dr. med. Georg Matheis, Managing Director of Novalung GmbH, explained: “Physicians and nurses will be able to respond to the individual patient’s therapeutic needs, regardless of whether he or she is lying in bed, sitting up or even starting to take a few steps.“
Novalung’s NovaPort® cannulas are known for their minimal flow resistance and excellent anti-kinking characteristics due to the high-flex design, while remaining extremely flexible. NovaPort® twin cannulas are introduced percutaneously using the familiar Seldinger technique. The integrated single-step dilator is especially gentle on the vessel walls. Since its inception Novalung has focussed on „Made in Germany“ to maintain the high quality of its products.
Über Novalung GmbH
Objective: replacing the invasive mechanical ventilation
Novalung‘s mission is the creation of new Solutions for Lung Failure using artificial lungs that breathe for the patient outside the body. Instead of placing patients in an artificial coma so that they can tolerate mechanical ventilation, Novalung products enable the patients to experience their treatment while awake, mobile and breathing easily. The innovative technologies open the door for physicians and nurses to this vision. The overall objective is to replace damaging invasive mechanical ventilation.
iLA activve®: all-rounder for lung support
Therapy objective with iLA activve® is, to support patients with lung failure while being awake and mobile instead of placing them into an artificial coma, ventilate them mechanically and to further damage the lung. The iLA activve® is a further step towards replacing invasive mechanical ventilation
The iLA activve® system has been specifically configured so that all necessary components are mounted on an easily movable trolley. Furthermore the iLA Membrane Ventilator® and the iLA activve® pump are height-adjustable via a quick-release handle so that physicians and nursing staff can easily react to the patient’s individual needs depending on whether the patient wants to lie in bed, sit up or even go a few steps.
Diverse patients and diverse types of lung support place different demands on an optimal lung support. To cover all individual needs with one therapeutic system, the iLA activve® has been developed as a flexible all-rounder. The veno-venous iLA activve® system covers the full range of respiratory support: from highly effective carbon dioxide elimination to complete oxygenation.
Founded in 2003, the German company Novalung GmbH operates on a highly international level in order to establish new solutions for lung failure. These advanced technologies from Germany and the U.S. were brought into the company and developed further.
From the outset Novalung has focused on high-quality development and production “Made in Germany“. Cutting-edge technologies are employed in Novalung’s medtech production facility in the manufacture in particular of the iLA Membrane Ventilator® and NovaPort® vascular access cannulas, both of which have been used to help treat thousands of patients.
The privately funded Novalung GmbH is a fast growing medical technology company based in the area of Heilbronn/Germany and with a subsidiary on the campus of the University of Michigan in Ann Arbor, USA.
Weitere Pressemitteilungen dieses Herausgebers
- 15.10.2012 - Gambro and Novalung join forces to address unmet medical need of CO2 removal in the Intensive Care Unit
- 15.10.2012 - Gambro und Novalung kooperieren, um neue Therapieoptionen für die Kohlendioxid-Entfernung in der Intensivmedizin zu entwickeln
- 10.10.2012 - Novalung GmbH receives EU grant for the development of a cell-coated artificial lung